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Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an inborn error of lysine catabolism that presents with refractory
epilepsy in newborns. Biallelic ALDH7A1 variants lead to deficiency of α-aminoadipic semialdehyde
dehydrogenase/antiquitin, resulting in accumulation of piperideine-6-carboxylate (P6C), and secondary deficiency of the
important cofactor pyridoxal-5′-phosphate (PLP, active vitamin B6) through its complexation with P6C. Vitamin B6
supplementation resolves epilepsy in patients, but intellectual disability may still develop. Early diagnosis and treatment,
preferably based on newborn screening, could optimize long-term clinical outcome. However, no suitable PDE-ALDH7A1
newborn screening biomarkers are currently available.
We combined the innovative analytical methods untargeted metabolomics and infrared ion spectroscopy to discover and
identify biomarkers in plasma that would allow for PDE-ALDH7A1 diagnosis in newborn screening.
We identified 2S,6S-/2S,6R-oxopropylpiperidine-2-carboxylic acid (2-OPP) as a PDE-ALDH7A1 biomarker, and confirmed
6-oxopiperidine-2-carboxylic acid (6-oxoPIP) as a biomarker. The suitability of 2-OPP as a potential PDE-ALDH7A1
newborn screening biomarker in dried bloodspots was shown. Additionally, we found that 2-OPP accumulates in brain
tissue of patients and Aldh7a1-knockout mice, and induced epilepsy-like behavior in a zebrafish model system.
This study has opened the way to newborn screening for PDE-ALDH7A1. We speculate that 2-OPP may contribute to
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Background. Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an inborn error of lysine catabolism that presents with
refractory epilepsy in newborns. Biallelic ALDH7A1 variants lead to deficiency of α-aminoadipic semialdehyde dehydrogenase/
antiquitin, resulting in accumulation of piperideine-6-carboxylate (P6C), and secondary deficiency of the important cofactor
pyridoxal-5′-phosphate (PLP, active vitamin B6) through its complexation with P6C. Vitamin B6 supplementation resolves
epilepsy in patients, but intellectual disability may still develop. Early diagnosis and treatment, preferably based on newborn
screening, could optimize long-term clinical outcome. However, no suitable PDE-ALDH7A1 newborn screening biomarkers are
currently available.
Methods. We combined the innovative analytical methods untargeted metabolomics and infrared ion spectroscopy to
discover and identify biomarkers in plasma that would allow for PDE-ALDH7A1 diagnosis in newborn screening.
Results. We identified 2S,6S-/2S,6R-oxopropylpiperidine-2-carboxylic acid (2-OPP) as a PDE-ALDH7A1 biomarker, and
confirmed 6-oxopiperidine-2-carboxylic acid (6-oxoPIP) as a biomarker. The suitability of 2-OPP as a potential PDE-ALDH7A1
newborn screening biomarker in dried bloodspots was shown. Additionally, we found that 2-OPP accumulates in brain tissue
of patients and Aldh7a1-knockout mice, and induced epilepsy-like behavior in a zebrafish model system.
Conclusion. This study has opened the way to newborn screening for PDE-ALDH7A1. We speculate that 2-OPP may contribute
to ongoing neurotoxicity, also in treated PDE-ALDH7A1 patients. As 2-OPP formation appears to increase upon ketosis, we
emphasize the importance of avoiding catabolism in PDE-ALDH7A1 patients.
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Figure 1. Overview of the L-lysine metabolic pathway involved in pyridoxine-dependent epilepsy. Diminished function of the enzyme α-aminoadipic
semialdehyde (α-AASA) dehydrogenase (antiquitin) encoded by the ALDH7A1 gene (indicated by red cross) leads to accumulation (indicated by red upward
arrows) of α-AASA, its cyclic counterpart piperideine-6-carboxylic acid (P6C), and pipecolic acid.

Introduction

Pyridoxine-dependent epilepsy due to biallelic ALDH7A1 variants (OMIM 266100, PDE-ALDH7A1) is an inborn error of
metabolism (IEM) that presents with refractory seizures in early
infancy. These seizures are typically unresponsive to anticonvulsant medications, but can be controlled with supplementation of pyridoxine (vitamin B6). ALDH7A1 encodes the enzyme
α-aminoadipic semialdehyde (α-AASA) dehydrogenase, which
is also known as antiquitin. Deficiency of this enzyme disrupts
lysine catabolism at the level of the conversion of α-AASA to
α-aminoadipic acid (Figure 1), leading to accumulation of α-AASA
and pipecolic acid in body fluids (1, 2). α-AASA is found in equilibrium with its alternative molecular form Δ1-piperideine-62

carboxylic acid (P6C), which is formed by spontaneous cyclization. Subsequent condensation of accumulating P6C with pyridoxal 5′-phosphate (PLP) results in secondary deficiency of active
vitamin B6, which is thought to be the main pathophysiological
mechanism in PDE-ALDH7A1 (3). By supplementing patients
with vitamin B6, this secondary deficiency can be corrected.
Vitamin B6 supplementation is therefore a cornerstone of seizure treatment in PDE-ALDH7A1, although some patients may
require add-on anticonvulsant medication for optimal seizure
control (4). Recent studies have shown that a lysine-restricted
diet can also be beneficial for ensuring optimal developmental
outcome in these patients, but only if such a diet is started in
the first year of life (5–8). Furthermore, the addition of arginine
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Figure 2. Molecular identification of unknown biomarkers in PDE-ALDH7A1 from untargeted metabolomics/NGMS data using IRIS. Matching overlay of
the IR spectra of biomarker A (A, m/z 186.1123 and retention time [RT] 2.33 minutes), biomarker B (B, m/z 186.1123 and RT 2.55 minutes), and biomarker
C (C, m/z 144.0652 and RT 3.05 minutes) measured in PDE-ALDH7A1 patient plasma (black traces) and the IR spectra of the protonated 2S,6S-2OPP (A),
2S,6R-2-OPP (B), and 6-oxoPIP (C) ions measured from synthetic reference standards (red traces). Molecular structures of the ions are inlaid in each panel.

supplementation to this treatment regimen, referred to as triple
therapy, has been shown to improve neurodevelopmental outcomes when started early in life (7, 8). Arginine competes with
lysine for transport across the blood-brain barrier and therefore
lowers the flux through lysine catabolism in the brain. At the biochemical level, triple therapy has been shown to lower levels of
P6C, α-AASA, and pipecolic acid in plasma and cerebrospinal
fluid (CSF) of treated PDE-ALDH7A1 patients (7, 8).
In order to optimize clinical outcome, it is crucial that the
diagnosis of PDE-ALDH7A1 is made as early as possible in life.
The combination of readily available disease-modifying therapeutic options, the potential risk of additional brain damage upon
delayed diagnosis, along with a reasonably high incidence of this
rare disease (estimated 1:64,000 conceptions) (9) make PDEALDH7A1 an eligible condition for inclusion in newborn screening programs. However, this is presently not implemented, as optimal biomarkers for dried blood spot (DBS) analysis in newborn
screening are not available. The current tools for rapid diagnostic
screening for PDE-ALDH7A1 encompass analysis of α-AASA and
P6C in urine (10). These compounds pose preanalytical challenges regarding stability, both in urine as well as in plasma and DBS,
where the limited stability at room temperature is a bottleneck for
including these markers in DBS-based newborn screening (11).
Analytical methods have been published that attempt to circumvent this; however, these are incompatible with commonly used
newborn screening workflows, which make use of direct-infusion
mass spectrometry (MS) without separation by liquid chromatography (LC) in order to avoid time-consuming derivatization steps
to enable high throughput (12–14). Therefore, there is a clear clinical need for other biomarkers to be able to include PDE-ALDH7A1
in newborn screening.
Additionally, clinical observations in PDE-ALDH7A1 patients
suggest that our current understanding of disease pathophysiology is likely incomplete. Intellectual disability is present in many
patients despite seizure control with pyridoxine, and in a subset of
patients, progressive brain MRI abnormalities are observed with
enlargement of ventricles and progressive white matter and corpus callosum abnormalities (15–19). In episodes of intercurrent

febrile illness, breakthrough epileptic seizures can occur despite
ongoing vitamin B6 treatment. In fact, according to data from the
online PDE registry (5), breakthrough seizures manifest in almost
40% of the 116 patients enlisted in the registry. Also, a substantial
percentage of patients still requires add-on classical anticonvulsant drugs (18%, based on PDE registry data; ref. 4). The molecular mechanisms underlying all these clinical observations are
unknown, but they are suggestive of biochemical disease sequelae
that go beyond our current understanding of disrupted lysine
metabolism in PDE-ALDH7A1.
To address both the need for novel diagnostic biomarkers
for PDE-ALDH7A1, as well as the need for deeper insights in
the biochemical effects of α-AASA dehydrogenase deficiency,
unbiased screening of the metabolic profile of patient body fluids is a crucial step. This can now be achieved through an innovative high-resolution MS–based technique referred to as untargeted metabolomics. In our laboratory, we have established an
untargeted-metabolomics method for broad diagnostic screening
of IEMs, coined next-generation metabolic screening (NGMS;
ref. 20), which we have now applied in search of novel biomarkers for PDE-ALDH7A1. We have previously shown the potential
of such an approach in the identification of novel IEM biomarkers and increasing pathophysiological insights in disease (21, 22).
However, the structural elucidation of unknown features/
novel metabolites from untargeted-metabolomics data remains
a significant challenge. To overcome this challenge, we used a
combination of NGMS and infrared ion spectroscopy (IRIS) for
orthogonal structural identification (23–28). Using this innovative
methodology, we were able to identify discriminative biomarkers for PDE-ALDH7A1, which can be measured in urine, plasma,
and CSF, as well as in DBS. Our findings further pave the way for
inclusion of PDE-ALDH7A1 in newborn screening, increase our
insights into underlying disease mechanisms, and may pose clinical implications for patient management.

Results

Untargeted metabolomics/NGMS identifies biomarkers in body fluids
of PDE-ALDH7A1 patients. We performed untargeted metabolom-
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Table 1. Untargeted metabolomics/NGMS results for biomarkers in PDE-ALDH7A1 patient body fluids
Feature
Biomarker A [M + H]+
Biomarker B [M + H]+
Biomarker C [M + H]+
α-AASA [M – H]–
P6C [M + H]+
Pipecolic acid [M + H]+

m/z

RT (min)

Fold change, plasma

Fold change, CSF

186.1123
186.1123
144.0652
144.0666
128.0706
130.0861

2.33
2.55
3.05
0.86
0.86
1.04

200
145
45
8
9
3

Diagnostic
Diagnostic
7
Diagnostic
Diagnostic
10

All 6 features shown in Table 1 were found to be significantly increased (P < 0.05 by 2-sided t test with Bonferroni-Holm correction) in PDE-ALDH7A1
patient plasma (n = 11) and CSF (n = 2) compared with controls (n = 30 for plasma, n = 10 for CSF) (as described in the Methods section). The mean fold
change in intensity is indicated (rounded to 0 or 5 as last digit for values >10), and the adduct with the highest fold change is shown, either the [M + H]+
adduct generated in the positive ionization mode, or the [M – H]– adduct from the negative ionization mode. “Diagnostic” indicates that the feature was
below the detection level in most control CSF samples (zero value), so no absolute fold change could be calculated, but was significantly increased in PDEALDH7A1 patient CSF. In one urine sample tested with NGMS, increased features corresponding to the biomarkers identified in this study could also be
detected (data not shown). m/z, mass over charge ratio; RT (min), retention time in minutes.

ics/NGMS in 11 plasma samples from 7 PDE-ALDH7A1 patients
(3 female and 4 male patients, mean age at sampling 14 years, age
range 3–28 years). Upon selection of features that were significantly increased in all patient plasma samples compared with non-IEM
controls, we could readily identify features corresponding to the
known biomarkers α-AASA, P6C, and pipecolic acid. Additionally,
2 isobaric features with a mass over charge ratio (m/z) of 186.1123
and retention times (RTs) of 2.33 minutes (biomarker A, mean
200-fold change compared with controls) and 2.55 minutes (biomarker B, mean 145-fold change compared with controls), as well
as a third feature with an m/z of 144.0652 and RT of 3.05 minutes, (biomarker C, mean 45-fold change compared with controls)
were identified as significantly increased in all patient samples.
Subsequently, we confirmed increased levels of these unknown
features in 2 CSF samples of PDE-ALDH7A1 patients. We could
also detect these features in a PDE-ALDH7A1 urine sample.
An overview of these findings is depicted in Table 1. Metabolite
annotation of these features based on their accurate mass using
the Human Metabolome Database (HMDB) only rendered ecgonine (HMDB0006548) and pseudoecgonine (HMDB0006348)
as matches for biomarkers A and B. These are tropane alkaloids
related to cocaine, so we considered this identification to be very
unlikely. For biomarker C, HMDB indicated multiple possible
matches to the exact mass; however, one of these matches, 6-oxopiperidine-2-carboxylic acid (6-oxoPIP, HMDB0061705), stood
out as a likely candidate because of its chemical similarity to P6C.
For molecular identification of biomarkers A and B, we
turned to a an approach using IRIS, which our group has recently
successfully applied for metabolite identification (23, 24, 27). In
short, MS fragmentation of biomarkers A and B gave a first hint
to their chemical composition, as an MS fragment corresponding
to P6C could be detected with an m/z of 128.0706. Through the
comparison of in silico–generated IR spectra for putative chemical
structures of biomarkers A and B to their experimental IR spectra
as measured from PDE-ALDH7A1 patient plasma, we were able
to further pinpoint their chemical structure without using reference standards. Based on this preliminary structural assignment
using predicted IR spectra, we could focus on synthesis of only
4

the predetermined compounds assigned to biomarkers A and B
for use in final confirmation of their structures, and as analytical
standards for the development of targeted MS–based diagnostics.
Using this approach, we were able to identify biomarkers A and
B as 2 diastereomers of 2-oxopropylpiperidine-2-carboxylic acid
(2-OPP, 2S,6S and 2S,6R conformations, respectively; Figure 2, A
and B). A detailed description of the IRIS strategy for molecular
identification of the 2-OPP diastereomers goes beyond the scope
of this current publication, but is elaborately described in a separate manuscript by van Outersterp et al. (29). For biomarker C, a
reference standard of 6-oxoPIP was commercially available, and
by comparison of its IR spectrum to the IR spectrum measured for
the signal observed in patient body fluids, we were able to confirm the identity of biomarker C as 6-oxoPIP (Figure 2C). During
the preparation of this manuscript, 6-oxoPIP was reported by 2
independent studies as a novel PDE-ALDH7A1 biomarker (30,
31). However, its suitability for detection in DBS using a directinfusion MS method, which is commonly used for newborn
screening, was not evaluated in these studies, as Wempe et al. (30)
made use of an LC-MS/MS method for DBS measurement and
Kuhara et al. (31) only evaluated urine.
Quantitative LC-MS measurements of 6-oxoPIP and 2-OPP
in PDE-ALDH7A1 patient body fluids. To further examine the
suitability of 2-OPP and 6-oxoPIP as possible biomarkers for
PDE-ALDH7A1, we developed quantitative targeted assays for
these markers, using LC-MS/MS for analysis in plasma, urine,
and CSF. These methods are further described in the Methods
section and were validated according to ISO 15189 criteria. In
brief, we analyzed 11 available plasma samples, 8 urine samples,
and 9 CSF samples from a total of 15 PDE-ALDH7A1 patients (8
males, 7 females, mean age at sampling 13 years, age ranging
from 1 month to 28 years) who all had a genetically confirmed
diagnosis. These patients were on different treatment regimens
(or untreated) and we compared 6-oxoPIP and 2-OPP levels (the sum of the 2-OPP 2S,6S and 2S,6R diastereomers was
used) to anonymized, non-PDE control samples, which were
age matched as much as possible (Figure 3). The quantitatively
measured levels of 6-oxoPIP and 2-OPP in plasma showed sat-
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Figure 3. 2-OPP and 6-oxoPIP concentrations in PDE-ALDH7A1 patient body fluids. Absolute concentration of 6-oxoPIP and the sum of 2S,6S-2-OPP and
2S,6R-2-OPP in (A and B) plasma (n = 11), (C and D) urine (n = 8), and (E and F) CSF (n = 9) of PDE-ALDH7A1 patients (PDE) compared with non-IEM controls
(n = 16 for plasma, n = 16 for urine, n = 13 for CSF), as measured by quantitative LC-MS/MS. Different treatment regimens in patients are coded as follows:
open circles, untreated; filled squares, vitamin B6 supplementation; filled circles, vitamin B6 and arginine supplementation; filled triangles, vitamin B6
supplementation and lysine restriction; filled diamonds, vitamin B6 and arginine supplementation and lysine restriction; cross, therapy unknown. Data
are shown as the mean and interquartile range. All patient 2-OPP and 6-oxoPIP concentration ranges shown were significantly increased compared with
controls (Mann-Whitney U test; CSF 6-oxoPIP patients versus controls P ≤ 0.0008, all other conditions P ≤ 0.0001).

isfactory correlation to the corrected semiquantitative intensities measured using NGMS as described above (Supplemental
Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI148272DS1). In urine of PDEALDH7A1 patients, mean 6-oxoPIP levels were substantially
higher than 2-OPP levels (mean 6-oxoPIP 117.4 μmol/mmol cre-

atinine versus 2-OPP 2.6 μmol/mmol creatinine in urine). The
6-oxoPIP levels in urine found in our study were comparable to
those previously reported by Kuhara et al. (31). The difference in
concentration between 6-oxoPIP and 2-OPP was also observed
in plasma, though to a lesser extent as seen in urine (mean
6-oxoPIP 7.5 μM versus mean 2-OPP 3.1 μM in plasma), with
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Figure 4. NGMS analysis of PDE-ALDH7A1 patient brain tissue extract. Extracted-ion chromatograms in brain tissue extract of a PDE-ALDH7A1 patient
of (A) P6C, m/z 128.0706, retention time (RT) 0.92 minutes, (B) α-AASA, m/z 146.0812, RT 0.92 minutes, (C) 2S,6S-2-OPP and 2S,6R-2-OPP, m/z 186.1123,
RT 2.42 and 2.67 minutes, respectively, (D) 6-oxoPIP, m/z 144.0652, RT 3.17 minutes, and (E) pipecolic acid, m/z 130.0863, RT 1.07 minutes. The y axis represents relative NGMS intensity, and the x axis represents RT (minutes). Note that an in-source P6C fragment of both 2-OPP enantiomers is also observed
at RT 2.42 and 2.67 minutes (A).

6-oxoPIP levels in plasma being comparable to those reported
by Wempe et al. (30). However, in CSF, the difference in concentration was the other way around (mean 6-oxoPIP 0.5 μM versus
mean 2-OPP 2.1 μM in CSF). Overall, we found no clear withinsample correlation between 6-oxoPIP and 2-OPP levels (Supplemental Figure 2); however, a positive correlation for 6-oxoPIP
and 2-OPP in urine was found with the known PDE-ALDH7A1
urinary biomarker α-AASA (Supplemental figure 3). In all measured body fluids, PDE-ALDH7A1 patient samples could be distinguished from controls based on increased concentrations of
the biomarkers 2-OPP and 6-oxoPIP.
2-OPP and 6-oxoPIP are increased in PDE-ALDH7A1 patient
brain tissue and in plasma and brain tissue Aldh7a1-knockout mice.
To further evaluate the biological relevance of the PDE biomarkers identified in this study, we analyzed an available brain tissue
extract sample, obtained postmortem from a deceased PDEALDH7A1 patient, using our NGMS assay (Figure 4, A–E). The
clinical details of this deceased patient have been described previously (18, 32). In this brain tissue extract, we were able to confirm
the presence of features corresponding to the known PDE markers
P6C, α-AASA, and pipecolic acid (Figure 4, A, B, and E). Additionally, the biomarker 2-OPP (2S,6S and 2S,6R diastereomers) and
the recently described biomarker 6-oxoPIP could be observed in
the PDE brain tissue extract (Figure 4, C and D). Upon quantitative measurement, we determined that 2-OPP levels were approximately 5 nmol/gram cortical tissue and 6-oxoPIP levels were
approximately 29 nmol/gram. In a previous study, a P6C concentration of 8.14 nmol/gram was reported in this brain specimen,
and α-AASA was determined to be 13.02 nmol/gram (32). In brain
extracts of 4 non-PDE controls, 2-OPP and 6-oxoPIP levels were
below the detection limit of our quantitative assay. In a recently
described Aldh7a1-knockout (Aldh7a1-KO) mouse model (33), we
6

were also able to detect increased concentrations of 2-OPP and
6-oxoPIP in plasma (Figure 5, A and B) and brain extracts (Figure
5, E and F), supporting our findings from the human situation. The
known PDE-ALDH7A1 markers P6C, α-AASA, and pipecolic acid
(Figure 5, C, D, and G) were also found to be increased in brain
tissue of Aldh7a1-KO mice, with pipecolic acid accumulating at
remarkably high levels.
2-OPP is formed by reaction of P6C with acetoacetate under
physiological conditions. To gain further insight in the biochemical origin of 2-OPP as a biomarker for α-AASA dehydrogenase
deficiency, we performed additional experiments to mimic
physiological conditions for its formation. From the chemical
structure of 2-OPP, as well as from the chemical synthesis of the
2-OPP model compound, we envisioned that 2-OPP could likely
be formed in the body by the reaction of accumulating P6C with
the ketone body acetoacetate (Figure 6H). To further substantiate
this hypothesis, we incubated P6C with acetoacetate in different
matrices: water, phosphate-buffered saline (PBS), human (nonIEM) control plasma, or human control urine (Figure 6, A–G).
In all these incubation experiments we observed preferential
formation of the 2S,6S-2-OPP enantiomer; however, in plasma
there appeared to be comparable levels of both the 2S,6R- and
2S,6S-2-OPP enantiomers. Additionally, we incubated P6C with
plasma and urine of a patient who was in a ketotic state (based
on increased concentration of acetyl-carnitine in plasma and
3-hydroxy-butyric acid in urine; acetoacetate itself was not measured but was assumed to be elevated due to ketosis), and found
that 2-OPP was readily formed in both samples, with the ratio of
isomers similar to that found in the incubation experiments in
control urine and plasma as described above. Finally, we incubated P6C in control plasma without the addition of acetoacetate and found detectable but significantly lower levels of 2-OPP
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Figure 5. Biomarker analysis of Aldh7a1-KO mouse plasma and brain. Plasma concentrations in Aldh7a1-KO mice (n = 4) compared to WT mice (n = 4) of
(A) 6-oxoPIP, and (B) the sum of 2S,6S-2-OPP and 2S,6R-2-OPP. Mean and interquartile ranges are shown. KO levels were significantly increased compared
with WT (Mann-Whitney U test, P < 0.05). Extracted-ion chromatograms in brain tissue extract of Aldh7a1-KO mice of (C) P6C, m/z 128.0706, retention
time (RT) 0.93 minutes, (D) α-AASA, m/z 146.0812, RT 0.93 minutes, (E) 2S,6S-2-OPP, m/z 186.1125, RT 2.46 minutes, (F) 6-oxoPIP, m/z 144.0652, RT
3.18 minutes, and (G) pipecolic acid, m/z 130.0863, RT 1.06 minutes. Representative data from 1 out of 2 Aldh7a1-KO brain samples is shown. The y axis
represents relative NGMS intensity, and the x axis represents RT (minutes).

formed. We therefore hypothesize that, even in non-ketotic circumstances, low amounts of acetoacetate present in body fluids
of PDE-ALDH7A1 patients can react with accumulating P6C to
form micromolar levels of 2-OPP. The identity of the observed
features as 2-OPP was confirmed by obtaining IR spectra of the
two 2-OPP features and matching those to reference IR spectra
(Supplemental Figure 4). Additionally, we could confirm the specificity of 2-OPP as a PDE-ALDH7A1 biomarker, as we measured
2-OPP concentrations within the control range in highly ketotic
plasma of non–PDE-ALDH7A1 controls, and showed no correlation between increased acetyl(C2)-carnitine and 2-OPP concentration in conditions of massive ketosis (Supplemental Figure 5).
2-OPP shows epileptogenic potential in a zebrafish model system.
As we were able to confirm the presence of 2-OPP in CSF and
brain extracts of PDE-ALDH7A1 patients and Aldh7a1-KO mice,
we were interested to follow up on the hypothesis that this metabolite may contribute to the epilepsy phenotype in patients. Toward

this end, we subjected zebrafish larvae to different concentrations
of 2-OPP and compared induced behavior to that after exposure to
pentylenetetrazole (PTZ), a positive-control compound known to
induce epilepsy-like behavior in zebrafish (34).
Measurement of baseline behavioral activity of the zebrafish
larvae 5 days post fertilization (dpf) revealed that 2-OPP significantly increased baseline activity at a concentration of 10 mM in
the swimming water (Figure 7A). Upon testing of a 1 μM to 10 mM
2-OPP concentration range in the swimming water, this effect
of increased locomotor activity was notable at a concentration
of 1 mM, but statistical significance was only reached at 10 mM
2-OPP. This finding corresponded with detection of increasing
2-OPP intensities in zebrafish full-body lysates with higher concentrations of 2-OPP exposure (Supplemental Figure 6). All larvae
survived for at least 24 hours at the tested doses, indicating that
this effect does not result from immediate toxicity. To investigate
whether 2-OPP induces seizure-like hyperactive behavior at 10
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Figure 6. 2-OPP is formed from P6C and acetoacetate (AcAc). Upon incubation of 1 mM P6C with 1 mM AcAc in different matrices — (A) H2O, (B) PBS, (C)
control plasma, and (D) control urine — 2-OPP formation was observed at elevated levels. Elevated 2-OPP formation was also observed upon incubation of
1 mM P6C with ketotic plasma (E) and urine (F). In the negative control incubation in plasma, including P6C but without the addition of AcAc, significantly
lower 2-OPP signals were detected (G). The y axis represents relative NGMS intensity (104 or 106 scale), and the x axis represents RT (minutes). (H) The
proposed chemical reaction for the formation of 2-OPP from AcAc and P6C (P6C is formed in equilibrium from α-AASA).

mM, zebrafish larvae were subjected to a previously published
behavioral paradigm of light/dark cycles (35). After the addition
of 2-OPP to the swimming water, larvae were allowed to acclimate
in the behavioral chamber for 15 minutes, after which they were
subjected to light/dark cycles. During the light flashes, 72.5% of
2-OPP–treated larvae displayed high-speed movements, as compared with 37.5% of control-treated larvae (Figure 7B). In addition, the cumulative duration of these high-speed movements
was significantly increased upon treatment with 2-OPP. Further
investigation of the observed hyperactive behavior during the
light-on periods and the entire period of light/dark cycles revealed
that larvae treated with 10 mM 2-OPP had higher movement frequency and travelled longer distances during these movements,
as compared with control-treated larvae (Figure 7, C–F). Typical
seizure behavior, with whole-body convulsions culminating in loss
of posture, was only observed in PTZ-treated larvae. However, the
hyperactivity upon 2-OPP treatment is in line with the seizure-like
8

hyperactivity that is described in the genetic zebrafish PDE model
(aldh7a1 mutant; ref. 35). This mutant displayed the first signs of
seizure-like convulsions at 11 dpf, indicating that a certain buildup
of metabolites might be required to induce this behavior.
Applicability of 2-OPP as a marker for PDE-ALDH7A1 in newborn screening. To set the first steps toward newborn screening for PDE-ALDH7A1, we also evaluated whether 2-OPP and
6-oxoPIP could be detected in DBS through a direct-infusion
MS method without derivatization. This MS method was developed to be compatible with reagents commonly used for neonatal screening (PerkinElmer NeoBase 2 Non-derivatized MS/MS
kit, which is for example used in the Dutch screening program).
During the development of this direct-infusion MS method for
DBS, it was apparent that for 6-oxoPIP, isobaric compounds
were present in control DBS that prevented adequate distinction of PDE-ALDH7A1 patients from controls, while for 2-OPP,
this was not the case (Supplemental Figure 7). Using the ratio
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Figure 7. Hyperactive behavior observed in zebrafish upon 2-OPP exposure. (A) Distance moved by 5 dpf zebrafish larvae after 10-minute treatment with
different concentrations of 2-OPP. PTZ was included as positive control of chemically induced seizure-like hyperactivity. (B) The percentage of zebrafish
larvae that display high-speed movements after exposure to a series of light flashes increased upon treatment with 10 mM 2-OPP (left y axis). The duration of the high-speed movements was also significantly increased by 2-OPP (right y axis). (C–F) The frequency of all movements and the distance that
the larvae moved were significantly increased during the light-on period (C and D) and during the entire 5-minute period of the light-flash paradigm (E and
F), indicating that the observed increase in activity does not solely result from an increased response to the light flash, but is indicative of hyperactivity
throughout the light-flash period. *P < 0.05; **P < 0.01; ***P < 0.001 by Kruskal-Wallis test (A) or Mann-Whitney U test (B–F).

between 2-OPP and hexanoyl/C6-carnitine, a marker already
included in the NeoBase kit, as a readout, we could clearly distinguish between 4 PDE-ALDH7A1 patients tested and non-PDE
controls (Figure 8). Of note, 2 of these PDE DBS were actual
neonatal screening samples from PDE-ALDH7A1 patients, and
had been stored for 12 to 13 years at room temperature before
the current analysis, indicating high stability of 2-OPP as a DBS
biomarker for PDE-ALDH7A1.

Discussion

In this study, the power of combining untargeted metabolomics
with IRIS for the identification of diagnostic biomarkers is illustrated. We applied this innovative technology to address the clinical need for novel biomarkers for the treatable metabolic epilepsy
syndrome PDE-ALDH7A1 to enable its inclusion in newborn
screening. This has allowed for the identification of 2-OPP and
6-oxoPIP as PDE-ALDH7A1 biomarkers accumulating in plasma, urine, CSF, and brain tissue. We have developed a quantitative LC-MS/MS assay for diagnostic application of 2-OPP and 6oxoPIP measurement in body fluids, adhering to ISO 15189 cri-

teria. Additionally, we have shown applicability of 2-OPP as a
first-tier, PDE-ALDH7A1 newborn screening biomarker in DBS,
through a direct-infusion MS method compatible with common
newborn screening workflows.
Regarding the biochemical relevance of 2-OPP in PDEALDH7A1 pathology, we have obtained initial evidence for
epileptogenic potential of this compound in a zebrafish model
system. Even though the tested concentration of 2-OPP in the
swimming water that induced epilepsy-like behavior in zebrafish larvae was significantly higher than the concentration
measured in body fluids and brain extracts of PDE-ALDH7A1
patients, it is likely that the actual 2-OPP concentration in the
zebrafish brain was much lower than the concentration added to
the swimming water. In line with this, relative 2-OPP intensity
measured with NGMS in full-body lysates of 10 mM 2-OPP–
exposed zebrafish larvae was comparable to 2-OPP intensity
measured in the human brain sample (intensity of ~7.5 × 105 in
Supplemental Figure 6F versus intensity of ~3 × 106 in Figure
4C). As we have shown 2-OPP accumulation both in human
patient and Aldh7a1-KO mouse brain tissue, it could be specu-
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Figure 8. 2-OPP–based diagnosis of PDE-ALDH7A1 in DBS using a
direct-infusion MS method. The y axis shows the relative intensity ratio
between 2-OPP and C6-carnitine, while on the x axis the categories of
non-PDE controls (n = 10) and PDE-ALDH7A1 patients (PDE, n = 4) are
plotted. Patient results were significantly increased compared with
controls (Mann-Whitney U test, P < 0.006). Patient results are marked
as follows: stars, neonatal DBS, untreated patients; filled squares, DBS
from 10-year-old patient on vitamin B6 supplementation; open circles,
DBS from untreated 16-year-old patient.

lated that 2-OPP exerts neurotoxic effects on the brain and may
in turn contribute to the ongoing-disease phenotype in treated
PDE-ALDH7A1 patients. However, this hypothesis requires further experiments to determine the exact mechanism of action of
2-OPP in the brain, as well as how concurrent accumulation of
α-AASA and P6C contributes to ongoing toxicity.
Of note, 2-OPP and 6-oxoPIP levels lacked a clear correlation
with treatment status or patient genotype. In urine, overall a positive correlation between 2-OPP and 6-oxoPIP concentrations and
levels of the known biomarker α-AASA was apparent. For most
human plasma and urine samples obtained in an untreated state,
the concentrations of 2-OPP and 6-oxoPIP were lower than those
observed in patients treated solely with vitamin B6. This likely
indicates that under treatment with vitamin B6 alone, substantial flux through the lysine pathway is ongoing and continues to
lead to the formation of P6C conjugates such as 2-OPP. Unfortunately, CSF samples from untreated patients were not available for analysis and comparison to the other body fluids, but it
was apparent that also in CSF, the highest 2-OPP and 6-oxoPIP
levels were measured in patients on vitamin B6 monotherapy.
We observed 2-OPP levels to be lowest in CSF for patients on B6
supplementation combined with arginine supplementation, with
or without additional dietary lysine restriction. Supplementation
with arginine competes with lysine for transport across the bloodbrain barrier via cationic transporters CAT1 and CAT2, and shows
an inverse relationship with CSF 2-OPP levels in the patients
included this study. Whether this biochemical finding in CSF correlates with clinical improvement, and is the result of arginine supplementation or lysine-reduction therapy in general, requires further study of well-characterized PDE-ALDH7A1 patients. Indeed,
we are planning such a study to evaluate the reliability of 2-OPP
and 6-oxoPIP as biomarkers for treatment monitoring and risk
stratification for PDE-ALDH7A1 patients.
Also, we identified additional unknown signals in the untargeted-metabolomics data that were significantly increased in
PDE-ALDH7A1 patient body fluids. We will continue the process of identification of these unknown features to possibly yield
additional insights into the biochemical consequences of α-AASA
10

dehydrogenase deficiency. Of note, upon measurement of the
2-OPP model compound in the HPLC/electrochemical system in
which previously an unknown compound (“Peak X”) was detected
in CSF of PDE patients by Hyland et al. (36, 37), it was apparent
that this “Peak X” could not be identified as 2-OPP (data not
shown), indicating that the identity of “Peak X” may still be waiting to be uncovered from our untargeted-metabolomics data.
Another interesting finding from our study, with possible
clinical implications, is the proposed mechanism of 2-OPP formation from the reaction of accumulating P6C with the ketone
body acetoacetate. This would imply that, especially in a state of
ketosis, the increased concentration of acetoacetate would further
drive 2-OPP formation in PDE-ALDH7A1 patients. As was stated
in the Introduction, in more than one-third of patients, breakthrough epilepsy occurs during intercurrent (febrile) illness, for
example gastroenteritis, despite increasing vitamin B6 dosage (15,
16). Catabolism often occurs during such episodes and, as is also
known for other IEMs, this can lead to increased flux through amino acid metabolism as well as to ketosis. Even though we have not
measured patient samples taken during such an intercurrent illness or period of reduced food intake, we speculate that increased
formation of 2-OPP due to ketosis may trigger breakthrough seizures, despite increased vitamin B6 dosage. Follow-up studies are
required to further substantiate this hypothesis, and could support
consideration of emergency plans for PDE-ALDH7A1 patients
during intercurrent illness aimed at avoiding catabolism and
ketosis. In the very recently updated consensus guidelines for the
diagnosis and management of PDE-ALDH7A1 (38), it is already
recommended to double the vitamin B6 dosage for a maximum
of 3 days and maintain caloric intake to prevent catabolism during
times of illness. Also, our current findings would again emphasize
the importance of early diagnosis, as a ketogenic diet, which is a
relatively common treatment in epilepsy, may be contraindicated
in PDE-ALDH7A1 patients. This should be further studied, as
there are currently no such cases reported in the literature.
Regarding the mechanism of formation of 2-OPP from P6C
and acetoacetate, our incubation experiments point to a possible
nonenzymatic process, as this reaction also takes place in water
and PBS. The only apparent difference with the reaction in plasma
was the observed ratio between 2S,6S-2-OPP and 2S,6R-2-OPP; in
the plasma incubation both enantiomers appeared, while in other
matrices the 2S,6S enantiomer was formed preferentially. While
the precise mechanism underlying the specific stereochemistry
involved in 2-OPP formation will require further study, variability
in the 2-OPP enantiomer ratio will not interfere with diagnostic interpretation of results in plasma, urine, or CSF, as in these
assays the sum of both 2-OPP enantiomers is used. Also for the
DBS assay, the enantiomer ratio will not lead to diagnostic issues,
as both enantiomers are detected simultaneously in the directinfusion MS method, which does not involve LC separation.
In conclusion, our research has uncovered 2-OPP and confirmed 6-oxoPIP as diagnostic PDE-ALDH7A1 biomarkers and
has also provided the first evidence to our knowledge for possible applicability of 2-OPP as a biomarker compatible with
direct-infusion MS approaches for newborn screening. To our
knowledge, our work represents the first example worldwide
of the successful application of untargeted, high-resolution MS
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Figure 9. Isotope-labeled standards of 6-oxoPIP and 2-OPP synthesized
for this study. *Denotes the position of 13C.

metabolomics in combination with IRIS for the identification
of a candidate biomarker for newborn screening of a treatable
neurometabolic disorder. Although whole-exome sequencing has been proposed as an alternative method for newborn
screening, which may partly replace separate biochemical
assays, a recent study emphasizes the crucial importance of
biochemical testing to reach an acceptable level of sensitivity
and specificity for newborn screening (39). To further confirm diagnostic specificity and sensitivity of 2-OPP as a firsttier PDE-ALDH7A1 screening biomarker, an extensive clinical
validation study should be initiated as a next step, screening
thousands of anonymized control neonatal DBS and additional
samples from patients using the direct-infusion MS method we
have developed. Based on our current results, we are now ready
to take on this next step to bring PDE-ALDH7A1 into newborn
screening. Additionally, our results pose potential clinical
implications regarding the importance of avoiding ketosis in
PDE-ALDH7A1 patients. We will further explore these insights
in future studies together with the international PDE Consortium and the PDE registry, ultimately to reach optimal clinical
outcomes for all PDE-ALDH7A1 patients through early diagnosis and personalized biochemical and clinical follow-up.

Methods

Sample collection. Heparin-anticoagulated plasma, urine, CSF, and/
or DBS of human PDE-ALDH7A1 patients had been previously collected for routine metabolic screening or treatment follow-up. For all
PDE-ALDH7A1 patients included, the diagnosis had been genetically
confirmed previously. Control samples were obtained from leftover
material from non-IEM patients and which did not show abnormalities in targeted-metabolite analyses. All plasma, urine, and CSF samples were stored in a digital alarm–controlled freezer at –20°C before
analysis, for a period ranging from 1 month to 9 years. The DBS were
stored at room temperature before analysis; neonatal DBS were stored
12 to 13 years, the spot from an untreated adolescent patient was kept
for 1.5 year at room temperature before analysis, while the spot of the
vitamin B6–treated child was stored 1 month before analysis. NonPDE control DBS had been stored at room temperature for a period of
between 8 and 20 months.
With regard to the human brain tissue samples, full-thickness
samples of the cerebral cortex from a 9-year-old female with PDEALDH7A1 were taken at autopsy 12 hours postmortem and placed at
–80°C. Clinical details on this patient were previously described (18,
32). Control brain tissue was obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland,
Baltimore, Maryland, USA. Cortical tissue was also obtained from
epilepsy surgery procedures. After excision, the fresh tissue was frozen in liquid nitrogen and stored at –80° C. For preparation of corti-

cal extracts, frozen cortical tissue (100–200 mg) was separated from
underlying white matter and homogenized in 5 mM Tris/HCl (pH 7.4)
with 0.32 M sucrose. The homogenates were centrifuged at 3000g
and 4°C for 5 minutes, and the resulting supernatant was then centrifuged at 40,000g and 4°C for 1 hour to pellet cellular membranes. The
supernatant from this centrifugation was used for subsequent sample
preparation for NGMS analysis.
The Aldh7a1-KO mouse model used in this study was generated
in accordance with guidelines of the Canadian Council on Animal
Care and was previously published (33). Mice used in this study were
housed in a pathogen-free barrier facility at the Centre for Molecular
Medicine and Therapeutics, University of British Columbia, Canada
and were given free access to food and water. Mice were fed a standard chow (Envigo 2018 Teklad Global 18% protein Rodent Diet) containing (w/w) 18% total protein, 0.9% lysine, and 18 ppm pyridoxine.
Aldh7a1-KO mice were backcrossed for at least 5 generations onto the
C57BL/6J background before generating cohorts for experiments,
such that all mice used were incipient congenic on the C57BL/6J background. Plasma and brain tissue from 4 Aldh7a1-KO (1 female and 3
males) and 4 WT mice (2 females and 2 males), all age 14 months,
were collected for metabolite analysis. Mice were anesthetized by
Avertin (2,2,2-tribromoethanol) injection or isoflurane inhalation.
The animals were then dissected, and blood was withdrawn directly
from the heart by needle and syringe. Blood was collected in heparin tubes and plasma was separated by centrifuging the blood tubes
at 3000 rpm for 10–15 minutes. Next, brain tissue samples were
harvested. All samples were snap-frozen with isopentane in dry ice
promptly after collection. Tissue and plasma samples were stored in a
–80°C freezer until shipment.
Extractions were performed for 2 Aldh7a1-KO and 2 WT mouse
brain tissues for NGMS analysis. For each tissue, a region containing
mainly the cerebellum was dissected, weighing approximately 1030
mg (range 1003–1078 mg). In an Eppendorf tube, 400 μL of methanol was added and the samples were centrifuged for 30 minutes at
18,600g and room temperature. The tissues were then pulverized
and centrifuged again for 20 minutes at room temperature. The
resulting supernatant was used for subsequent sample preparation
for NGMS analysis.
Sample preparation. Frozen plasma, urine, CSF, or tissue extract
samples were thawed at 4°C and mixed by vortexing. A sample aliquot of 100 μL was transferred into a 1.5 mL polypropylene microcentrifuge tube. Then, 400 μL ice cold methanol/ethanol (50:50 vol/
vol) containing 5 internal standards (0.88 μmol/L caffeine-d3, 0.22
μmol/L hippuric-d5 acid, 0.88 μmol/L nicotinic-d4 acid, 0.22 μmol/L
octanoyl-L-carnitine-d3, and 0.44 μmol/L L-phenyl-d5-alanine [all
from C/D/N Isotopes]) was added to each aliquot. The samples were
thoroughly mixed on a vortex mixer for 30 seconds. The samples were
incubated at 4°C for 20 minutes, after which they were centrifuged at
18,600g and 4°C for 15 minutes. An aliquot of 350 μL of the supernatant was transferred into a 1.5 mL polypropylene microcentrifuge tube.
Samples were dried in a centrifugal vacuum evaporator (Eppendorf) at
room temperature. The samples were reconstituted in 100 μL of water
containing 0.1% (vol/vol) formic acid, vortexed for 15 seconds, and
centrifuged at 18,600g and room temperature for 15 minutes. An aliquot of 90 μL was transferred into 250 μL polypropylene autosampler
vials. These samples were either placed in an autosampler operating at
4°C for direct analysis or stored at –80°C. Stored samples were thawed
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at room temperature and centrifuged at 18,600g and room temperature for 15 minutes before analysis.
NGMS. NGMS was performed as previously described (20). In
short, analyses were performed using an Agilent 1290 UHPLC system coupled to an Agilent 6545 QTOF mass spectrometer, equipped
with a dual electrospray ionization (ESI) source. Each sample was run
in duplicate in both positive and negative ionization modes. A 2.0 μL
aliquot of extracted plasma sample was injected onto an Acquity HSS
T3 (C18, 2.1 × 100 mm, 1.8 μm) column (Waters) operating at 40°C.
Chromatographic separations were performed by applying a binary
mobile phase system. Exact details of buffer composition and MS settings were as previously reported (20). Each analytical batch was composed of control samples, PDE-ALDH7A1 patient samples, analytical
quality control (QC) samples, and a validation plasma pool to check
for integrity of the automated data analysis pipeline. An analytical run
consisted of a maximum of 150 samples. Control and patient samples
were analyzed in duplicate. To correct for possible run-order influence
on signal intensities, these duplicates were analyzed in antiparallel run
order, meaning that duplicates of the first patient sample were analyzed in the first and last position in the analytical run, while duplicates of the last patient sample were analyzed in the 2 middle positions
of the run. Eight random control plasma samples were injected at the
start of each analytical batch in order to condition the analytical platform. For further details on the analytical QC procedure and requirements, please refer to Coene et al. (20).
NGMS data processing and statistics. The output files of the NGMS
runs were aligned using the open access software package XCMS
(online version 3.7.1/2.7.2, XCMS version 1.47.3; https://xcmsonline.
scripps.edu) in single-job modus (40). A complete description of
XCMS online parameter settings applied is listed in Supplemental
Table 1. Following alignment and feature extraction, features were
annotated against the Human Metabolome Database (HMDB; ref. 41)
for putative metabolite identification. For all features, 2-sided t tests
were performed to identify significantly altered features between an
individual patient and controls. These steps of alignment, annotation, and statistical testing were integrated in an in-house bioinformatic pipeline that was validated for diagnostic use against ISO 15189
standards. Because of the large number of features identified in an
individual patient sample (~10,000), the Bonferroni-Holm procedure
was used to correct for multiple testing to prevent false positives, i.e.,
features incorrectly marked as significantly different in a patient. Two
types of t tests were applied to compare the intensity of each feature
present in an individual patient sample to the intensities observed in
the control samples, as previously described (20). Only features that
were marked as significantly different by both t tests after BonferroniHolm correction (P value < 0.05) were retained for further analysis. Significantly different features were compared between PDEALDH7A1 patient samples to select common differential features.
IRIS MS. Analyte separations for the IRIS experiments were performed with a Bruker Elute SP HPLC system consisting of a binary
pump, cooled autosampler, and column oven using the exact same
separation method as described above for NGMS. Fractions containing the metabolites of interest were obtained by collecting the eluent
on 96-well plates using a Foxy R2 fraction collector. For these experiments, an injection volume of 20 μL was used.
IRIS experiments were performed in a quadrupole ion trap mass
spectrometer (Bruker, AmaZon Speed ETD) modified for spectros12

copy. Details of the hardware modifications and synchronization of
the experiment with the infrared laser are described elsewhere (42).
Collected LC fractions and solutions of reference compounds (~1 ×
10−7 M in 50:50 methanol/water) were introduced at 80–180 μL/h
flow rates to the electrospray source (+ESI). The ions of interest were
mass isolated and irradiated by the Free Electron Laser for Infrared
eXperiments (FELIX) for IR analysis. IR spectra were recorded with
FELIX set to produce IR radiation in the form of approximately 10
μs macropulses of 50–150 mJ at a 10 Hz repetition rate (bandwidth
~0.4% of the center frequency).
When the laser is resonant with a vibrational transition of the ions,
this leads to absorption of the IR photons, producing an increase in
the ions’ internal energy and eventually leading to photodissociation.
Thus, IR absorption can be observed by recording a fragmentation MS
spectrum. IR spectra were constructed by plotting the fractional dissociation [IR yield = ΣI(fragment ions)/ΣI(parent + fragment ions)] as a
function of IR laser frequency. The IR yield at each wavelength position of the laser was calculated from 4 to 8 averaged fragmentation
mass spectra. The IR frequency was calibrated using a grating spectrometer, and the IR yield was linearly corrected for frequency-dependent variations in the laser pulse energy.
P6C incubation experiments. P6C (from in-house synthesis, see
Supplemental Methods) was incubated at a 1 mM concentration
(based on Mills et al., ref. 3) with 1 mM acetoacetate (see Supplemental
Figure 8 for synthesis of acetoacetate, not commercially available) for
24 hours at 37°C in different matrices: H2O, PBS (pH 7.5), a non-IEM
control plasma pool, and a non-IEM control urine pool. The non-IEM
control urine pool consisted of a mixture of 4 random, anonymized
left-over samples from diagnostics, while the non-IEM control plasma
pool consisted of a mixture of 7 random, anonymized left-over samples. Also, 1 mM P6C was incubated for 24 hours at 37°C with a ketotic
urine sample (based on increased excretion of 3-hydroxybutyric acid)
and a ketotic plasma sample (based on increased concentration of
acetyl-carnitine). After the 24-hour incubation period, samples were
put on ice, and a 100 μL aliquot was taken for further processing for
NGMS analysis, equal to the sample preparation procedure described
above. The resulting samples were also used to record IR spectra
according to the procedure described above.
Zebrafish studies. WT Tüpfel long fin (EZRC), F4 generation
zebrafish were bred and raised in recirculation systems (temperature
~27°C, pH 7.5–8, conductivity ~320 μS/cm) under a 14-hour light/10hour dark cycle. Fish were fed twice daily with Artemia sp. and Gemma
Micro 300 (Skretting). Zebrafish eggs were obtained from natural
spawning, and raised in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33
mM CaCl2, 0.33 mM MgSO4, and 0.000013% methylene blue) at
28.5°C until experiments.
At 5 dpf, the zebrafish larvae were placed individually in a 96-well
plate containing 100 μL E2 medium (5 mM NaCl, 0.17 mM KCl, 0.33
mM CaCl2, and 0.33 mM MgSO4). At this early developmental stage,
zebrafish larvae are still asexual. Directly before larvae were subjected
to behavioral analyses, PTZ (at a concentration of 15 mM) or 2S,6R-2OPP (at a concentration of 1 μM, 10 μM, 100 μM, 1 mM, or 10 mM) was
added to the wells via 100 μL of a 2× stock solution of compound in E2
medium. Video tracking of larval behavior was performed in a DanioVision system and tracked with EthoVision XT14 software from Noldus Information Technology at 28.5°C. The seizure-inducing protocol
(35) consisted of 15 minutes of dark adaptation, followed by 5 cycles of
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the 96-well plate was placed back in the incubator and subjected to
the same behavioral paradigm after 24 hours of compound treatment.
Behavioral responses were analyzed with EthoVision XT14 software,
using start and stop velocities of 7.5 mm/s and 5 mm/s, respectively, to
determine movement frequencies, and a lower limit of greater than 20
mm/s to determine high-speed movements.
Synthesis of 13C isotope–labeled 6-oxoPIP and (2S,6R)-2-OPP. To
enable quantitative MS, 13C isotope–labeled 6-oxoPIP and (2S,6R)2-OPP derivatives were prepared, carrying 1 or 2 isotopic labels,
respectively (Figure 9). Briefly, (S)-2-aminohexanedioic-6-acid carrying a single 13C label was dehydrated to produce an isotope-labeled
6-oxoPIP analog. The (2S,6R)-2-OPP isotope-labeled standard was
prepared by reacting a protected P6C derivative with 13C-labeled acetone, followed by deprotection to produce the isotope-labeled derivative of (2S,6R)-2-OPP (see Supplemental Figures 8 and 9 and the Supplemental Methods for more details on the synthesis).
Quantitative LC-MS measurement of 6-oxoPIP and 2-OPP in body
fluids. Levels of 6-oxoPIP and 2-OPP were determined in plasma,
urine, and CSF using LC-MS/MS through a stable isotope dilution
(SID) method. Ten microliters of body fluid (for urine an equivalent
to a creatinine level of 0.1 mM) was diluted with 10 μL of stable isotope solution (5 μM 1,3-13C2-(2S,6R)-2-OPP and 0.5 μM 13C1-6-oxoPIP
in H2O; see Figure 9 and Supplemental Information for more details),
and 200 μL H2O. For plasma, SID was carried out in a 30 kDa centrifugal filter (Amicon Ultra 0.5 mL 30 kDa centrifugal filter regenerated
cellulose 30,000 MWCO, Millipore) to remove protein (15 minutes,
14,000g, 15°C). One microliter of the isotope-diluted sample was
injected into the HPLC-MS/MS system, which consisted of a Waters
I-Class Acquity fitted with an Atlantis T3 (2.1 × 100 mm, particle size
3 μm) column connected to a Waters Xevo TQSμ mass spectrometer.
The column was run at 400 μL/min in gradient mode using 0.5% acetic acid in H2O and acetonitrile (initial conditions: 100% 0.5% acetic
acid in H2O; gradient: 7.5% acetonitrile per minute) The column flow
was directed to the Xevo TQSμ fitted with an ESI probe operating in
the positive mode at unit resolution. The capillary voltage was set at
0.35 kV. The temperature settings for the source and ion block were
550°C and 150°C, respectively. As drying gas, nitrogen was used at a
flow rate of 800 L/h. The cone gas flow was set at 50 L/h. The collision cell was operated with argon as collision gas at a pressure of 0.35
Pa. For 6-oxoPIP and its stable isotope, a neutral loss of the carboxylic
group as -HCOOH was monitored (m/z 144.1 → m/z 98.1). For 2-OPP
and its stable isotope, the loss of the oxo-propyl group was monitored
(m/z 186.1 → m/z 128.1). Quantification was done by comparison of
the generated area response using the corresponding stable isotope as
internal standard. This method was validated according to ISO 15189
standards for use in clinical diagnostic procedures.
Direct-infusion MS measurement of 6-oxoPIP and 2-OPP in DBS.
Analysis of 6-oxoPIP and 2-OPP in DBS was performed using a
direct-infusion MS/MS method, similar to the NeoBase 2 nonderivatized MS/MS kit protocol. In short, DBS punches with a diameter of 6.35 mm were extracted with 300 μL methanol containing internal standards. Extraction was performed by shaking at 45°C and 100
rpm for 30 minutes. After a 30-minute cooling period, 50 μL of the
extract was diluted with methanol and 0.2% formic acid in H2O at a
ratio of 1:1:0.2. Using a Waters I-Class Acquity HPLC system, 10 μL of
the diluted extract was infused into a Waters Xevo TQSμ at 40 μL/min

using 80% acetonitrile and 20% 0.2% formic acid in H2O. The Xevo
TQSμ, which was set to monitor not only multiple reaction monitoring (MRM) transitions that are already part of the NeoBase protocol
but also the transitions 6-oxoPIP (m/z 144.1 → m/z 98.1) and 2-OPP
(m/z 186.1 → m/z 128.1). For every compound, optimized cone and
collision energies were used. The Xevo TQSμ was fitted with an electrospray probe and was operated at unit resolution. The capillary voltage was set at 3.0 kV. The temperature settings for the source and ion
block were 250°C and 150°C, respectively. As a drying gas, nitrogen
was used at a flow rate of 250 L/h. The cone gas flow was set at 50
L/h. The collision cell was operated with argon as the collision gas at
a pressure of 0.35 Pa. MS/MS response for 2-OPP and 6-oxoPIP was
normalized to the response for hexanoyl (C6)-carnitine, a metabolite
that is already analyzed in the NeoBase 2 kit. Hexanoyl-carnitine levels in control DBS were comparable to control levels for 2-OPP in DBS
and had a narrow control range, making hexanoyl-carnitine optimally
suited for ratio-based normalization.
Statistics. For comparison of concentration ranges of 2-OPP and
6-oxoPIP in body fluids between controls and PDE-ALDH7A1 patients,
a Mann-Whitney U test was used with P less than 0.001 as an overall
cut-off for statistical significance. For comparing Aldh7a1-KO mice to
WT mice, a Mann-Whitney U test was used with P less than 0.05 as
cutoff for statistical significance. For zebrafish experiments, distance
moved upon increasing concentrations of 2-OPP exposure were compared with a Kruskal-Wallis test, with a cutoff of P less than 0.05 for
statistical significance. A Mann-Whitney U test was used to compare
frequency of movements and total moved distance of 2-OPP–exposed
zebrafish, with P less than 0.05 considered statistically significant.
Study approval. All patients and control subjects (or their guardians) registered their informed consent for the possible use of their leftover body fluid samples from clinical diagnostics for laboratory method
validation purposes in their electronic patient record, in agreement with
institutional and national legislation, as reviewed by the accredited
Research Ethics Committee of Radboud University Medical Centre
(file number 2021–7296).
Written informed consent for the use of the human brain tissue
for research purposes was obtained from each subject or their legal
guardian, and was approved by the Institutional Review Board of Seattle Children’s Hospital (application number 11756).
The Aldh7a1-KO mouse model used in this study was generated in
accordance with guidelines of the Canadian Council on Animal Care
under an approved protocol from the University of British Columbia
Animal Care Committee (Animal Protocols numbers A15-0200, A150180, A14-0031, and A18-0117).
All zebrafish experiments were carried out in accordance with
European guidelines on animal experiments (2010/63/EU).
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